Med by Cell Press

Editor’s choice: Breakthrough findings from Cohort 5 of the DEBBRAH #BreastCancer trial: https://hubs.li/Q02Yv6L70

Last chance to register for the?Cell Press/The Lancet?webinar today: Perspectives on?#autistic?mental well-being, communication, and relationships.?Register here:?https://lnkd.in/ebivY4qk Speakers:?Sarah Chellappa, Yi Wang,?Catherine Crompton, and?Monique Botha

??New paper out in?Med by Cell Press! ??A pionering study, led by CNAG and?IrsiCaixa, identifies a unique immune profile in HIV patients who, despite not receiving antiretroviral treatment, resist disease infections. ? ??This group of patients, known as viremic non-progressors (VNPs), represent only a 0.1% of people with HIV wordlwide. ? ??The immune profile of VNPs marks a significant advancement in developing new therapeutic interventions for patients who experience HIV disease progression. ? ??Our researchers?at?#CNAG?studied the immune cells of HIV patients, including those who are resistant to disease progression and those who are not. Our team?recreated their cellular atlas, annotated and characterised the immune cells, and conducted a transcriptomic analysis.? ? ????The research was enabled by advanced technologies from CNAG and the key contributions of our Single Cell Genomics Group, including Holger Heyn,?Juan Nieto Sáchica, and?Ginevra Caratù, as well as?Raul Tonda?and Jordi Morata from the Variant Calling and Analysis Team (Bioinformatics Unit). ? ??https://lnkd.in/dxxPyZV6 #HIVResearch?#Immunology?#Genomics?#SingleCell?#HealthcareInnovation?#ScientificDiscovery?#MedCellPress

Our #clinical and #translational research hub is now live! Explore the page to learn more about our editors, including if they'll be in your area soon, and editorially curated content: https://hubs.li/Q02Y7S0H0

Online Now: Multi-year enzyme expression in patients with mucopolysaccharidosis type VI after liver-directed gene therapy https://dlvr.it/TGC9Df

Long-term follow-up of a clinical trial of AAV-mediated liver-directed gene therapy in patients with mucopolysaccharidosis type VI (MPS VI), a rare lysosomal storage disease https://lnkd.in/ey5YczyR The data show sustained ARSB expression and a modest increase in urine glycosaminoglycans. Despite discontinuation of enzyme replacement therapy, there were no significant changes in endurance, pulmonary, and cardiac function. The long-term follow-up data demonstrated the safety and efficacy of AAV-mediated liver-directed gene therapy as a potential treatment for MPS VI. Alessandro Rossi ?Roberta Romano? Simona Fecarotta ?Margherita Dell'Anno? Valentina Pecorella ?Roberta Passeggio ?Stefano Zancan giancarlo parenti ?Francesca Santamaria ?Francesco Borgia ?Federica Deodato ?Silvia Funghini ?Charles A. Rupar ?Chitra Prasad ?Maria Del Mar O'Callaghan ?John Mitchell??Maria Grazia Valsecchi??Giancarlo la Marca ??Stefania Galimberti??Alberto Auricchio ?Nicola Brunetti-Pierri Università degli Studi di Napoli Federico II (UniNa) / University of Naples Federico II Fondazione Telethon Telethon Kids Institute Ospedale Pediatrico Bambino Gesù Azienda Ospedaliera Universitaria Meyer - IRCCS Western University Barcelona Children's Hospital Sant Joan de Déu Centre universitaire de santé McGill | McGill University Health Centre Università degli Studi di Milano-Bicocca Fondazione IRCCS San Gerardo dei Tintori Università degli Studi di Firenze #MPSVI #GeneTherapy #LiverDirectedTherapy #AAV #ARSB #Glycosaminoglycans #RareDisease #ClinicalTrial

Online Now: A cluster randomized trial of xylitol chewing gum for prevention of preterm birth: The PPaX trial https://dlvr.it/TGB667

In a cluster randomized trial conducted in Malawi, researchers found that the use of xylitol-containing chewing gum during pregnancy reduced the occurrence of preterm and low-birthweight deliveries compared to standard prenatal care https://lnkd.in/d4ejU3bX The trial involved over 10,000 pregnant participants and showed that xylitol gum use led to fewer neonatal demises without significant adverse events reported. This approach could be an efficacious and affordable strategy for preventing preterm and low-birthweight deliveries in high-prevalence populations. Gregory C. Valentine ? Kathleen M. Antony ? Haleh Sangi-Haghpeykar, Ph.D. ? Alexis Wood ? Rose Chirwa ? Saukani Petro ? Mary Dumba ? Deborah Nanthuru ? Cynthia Shope ? Jesse Mlotha-Namarika ? Jeffrey Wilkinson ? Joshua Aagaard ? Ellen J. Aagaard ? Maxim Seferovic ? Levison Judy ? Peter Kazembe ? Kjersti Aagaard Baylor College of Medicine Baylor Foundation Malawi University of Washington University of Wisconsin-Madison kamuzu central hospital, Lilongwe, Malawi St. Olaf College Baylor University, Waco, TX, USA HCA Healthcare and HCA Healthcare Research Institute and HCA Healthcare Texas Maternal Fetal Medicine, Nashville, TN, Houston, TX, USA Boston Children's Hospital Harvard Medical School #PregnancyHealth #PretermBirth #LowBirthweight #XylitolChewingGum #MaternalHealth #NeonatalOutcomes # PPaXtrial #PrenatalCare #GlobalHealth

New research from Mass General Brigham shows an AI-powered approach to identifying long COVID cases within patient health records, helping clinicians with diagnosis and potentially revealing a clearer view of the pandemic’s ongoing impact. This new algorithm—developed by Hossein Estiri, PhD, and colleagues—uses a method called “precision phenotyping” to sift through symptoms over time and exclude alternative explanations, providing a nuanced diagnosis for long COVID. “Physicians are often faced with having to wade through a tangled web of symptoms and medical histories, unsure of which threads to pull, while balancing busy caseloads. Having a tool powered by AI that can methodically do it for them could be a game-changer,” said Alaleh Azhir, MD, the co-lead author on the study. Read more about the study published in Med by Cell Press: https://lnkd.in/gqFu5TQB #longcovid #ai #aiinhealthcare #artificialintelligence

Online Now: No association between the early-life gut microbiota and childhood body mass index and body composition https://dlvr.it/TG920g